Northwest Biotherapeutics Inc (QB) (NWBO) Quote

Eye rolls.

Michael Bigger actually posted the ASM audio on Twitter, as a means to give those who were not among the 600 an opportunity to listen in. He was impressed with LP's explanation of Flashworks advancements etc.

The delay in preparing the MAA was because the consultants responsible for preparing the MAA application completely dropped the ball and messed up the initial application. From what I heard Bosch and Powers got together and produced a solid and correct application which caused the delay.
At least that's what I heard.

Not surprised , that usual folks here will start calling him basher as well . Anyone who doesn’t fall in line ….!!!

LOL. Anyone starting to ridicule Bigger here you should just ignore as total shills. I'm shocked how patient he's been (and stupid).

Could Michael Bigger, JF Rule and the rest of the Canadian cohort be involved in a desperate search for relevance?

Trying to discredit Linda Powers and the NWBO management team is hardly the way to succeed!

I recommend that they listen to the recently posted ASM audio on the NWBO website and realize that it would take all of them more time collectively that they have spent on earth to accomplish what LP has accomplished in the last 18 months. AND their visionary deficiencies will never allow them to develop a plan to continue to build franchise value of the kind revealed by Linda Powers in her ASM Presentation.

Cheers,

BB

Senior Scientist / Associate Director, Omics at insitro

The Opportunity

High quality data generation with state-of-the-art technologies that measure multiple cellular aspects is at the heart of Insitro's efforts to accelerate drug development. In particular the omics platform integrates state-of-the-art functional and observational genomics technologies to interrogate the genes, proteins, and signaling networks that characterize individual cellular states.

We are seeking a highly motivated and independent team member with deep expertise in sequencing based readouts. The successful candidate will possess a deep-knowledge of methods for NGS library preparation (RNA-seq, Ribo-seq, ATAC-seq, ChIP-seq, Hi-C, etc.) as well as hands-on experience with various sequencers (Illumina, Nanopore, PacBio, etc). You will work in a fast-paced and highly collaborative environment to address important questions from our research community. Specifically, you will employ the latest genomic tools to interrogate these questions in close collaboration with all teams across insitro. Your expertise will help the team navigate the complexities of generating high quality transcriptomics data and ensure that the protocols being developed are effective, performed to the highest rigor and in line with best practices in the field.

In this role, you will directly impact all target discovery and prioritization efforts, advance our understanding of diseases and aid the development of new treatments. In general, as a staff genomics scientist at insitro, you will be in charge of establishing platforms and workflows to enable the generation of high quality sequencing data, generating large scale datasets paired with other modalities, and enabling multimodal measurements and data integration. You will be part of a cross-functional team of life scientists, data scientists, bioengineers, software engineers, and machine learning scientists that strive to identify therapeutic targets and develop drugs of high efficacy and low toxicity.

You will be joining a vibrant biotech startup that has long-term stability, due to significant funding, and is in a high growth phase, and you will have many opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro's culture, strategic direction, and outcomes. Join us, and help make a difference to patients!

Responsibilities

Implementing sequencing protocols and platforms (Illumina, PacBio, Nanopore, etc), as well as functioning independently to explore and develop new genomic technologies.
Leading and participating in collaborative genomic projects.
Responsible for interfacing with other labs and cores to identify opportunities for research & collaboration
Responsible for inventing, optimizing and maintaining state-of-the-art approaches in collaboration with scientists.
Responsible for working with scientists to develop project-specific experimental strategies, techniques, and procedures, and to interpret and model data.
Overseeing a range of duties supporting and developing laboratory operations and administration for sequencing workflows.
Writing protocols and presenting research work internally and externally.

About You

8+ years of working experience post MSc with sequencing based workflows and readouts. Must have hands-on experience with library quantification with ddPCR/qPCR and with operating various sequencers (Illumina, Nanopore, or PacBio). Must have hands-on experience with NGS library preparation, in particular with single cell sequencing library preparation (10X genomics, SMART-seq2 and Split-and-Pool methods, etc.)
Ability to work independently and lead projects.
Hands-on experience with spatial transcriptomics and/or proteomics data generation.
Some understanding of human physiology or disease biology (e.g. neurosciences, cancer biology).
Experience with CRISPR-based experiments (i.e. perturb-seq).
Ability to communicate effectively and collaborate with people of diverse backgrounds and job functions.
Passionate about troubleshooting, asking questions and learning independently.
Familiarity with software tools (e.g., bcl2fastq, cellranger) and bioinformatics.
Passion for making a difference in the world.

Nice to Have

Working knowledge of large-scale single cell / bulk CRISPR screens in various settings including in vivo, ex vivo, and cell line systems is highly desirable.
Experience with lab automation is highly desired.
Publication record of meaningful contributions to high-quality work in relevant computational biology, systems biology, life sciences, or biomedical venues.
First-hand experience studying diseases using omics data.Experience building genomics teams

https://boards.greenhouse.io/insitro/jobs/4379887006

Or maybe because he's on the BOD???

You're talking about one very unusual event compared to the other 99% of dead wood public companies that replace lousy management and either go on to disappear or provide shareholders a return.

Bad math. If you use $250 per treatment it is $250 million. At least get the math straight. Specials were about $250K.

You stated this.

“About 1000 vaccines from the artisan method a year for time being will easily bring in 1.5B revenue. Go NWBO!”

And they eventually brought back Steve jobs to finish the job he started. So you want to kick Linda out today or five years ago only to bring her back now.

Apple went through many management changes. NWBO has the exact same crew minus a few, of course.

And again, who really cares about something that happened 20 years ago in a company history. It’s nice to remember it, but the company will be evaluated on what happens in the next 18 months not something that happened 20 years ago.

Why don’t you bring up Apple computer when they basically went out of business in the late 80s then resurrected themselves a couple of times over and now look at them

Let's assume I am. Shareholders have lost 99.X% of their hard earn money over a decade plus so am I right?

>>You are fear mongering

You are fear mongering trying to pretend that they can just go out and sell our technology to any bitter just to drum up clicks. Again keep throwing shit against the wall.

BioHarm already told you it's not. Not every can be patented but can try to be protected.

>>It’s protected IP..

Evaluate (as I rub my eyes to get a clearer focus), is that you? 😵

More fear mongering .. what can they do with it ..

It’s protected IP..

And it’s been improved upon since then

Cool. Quote the guy who has been wrong 100% of the time.

I don’t recall the dates of the reverse splits

Because as ancient history they don’t matter to what I do today …

But yet I have been in and out of this stock since 2009

But you keep FUDDING along

Maybe someone else will care

That's what you call "Skating on thin ice". LOL. The idea that Cognate didn't take some of NWBO sponsored knowledge with them is poppycock!

Sorry if I sounded grumpy. Understood. She did not sell them anything period and I do not believe they can monetize, directly, anything from doing NWBO’s manufacturing, especially not manually. I think the key point is, let’s not suggest anything was sold, to them, from NWBO, because there is nothing suggesting that. Let’s not feed shorts and then argue with them about things that are not real. Cognate can help other companies develop their own IP, but working with the cells was likely already part of the general art, and for the things NWBO patented, they’d need a license to use even if they have personnel who helped invent some ideas. And some ideas are likely less consequential than others. And of course Flaskworks creates a whole new class of technologies and patents.

Ok ok sorry for my ignorance; I misinterpreted it. Thanks for letting me know.

I'll certainly agree with you there.

By the way, here's a great article on naked shorting thanks to Xena on AVXL.

https://oilprice.com/Energy/Energy-General/Naked-Short-Selling-The-Truth-Is-Much-Worse-Than-You-Have-Been-Told.html

Gary

LOL. I'm reading a political article in the Spectator by Scott McKay and this sentence jumped out at me, so I took the liberty of changing a few words:

The skeptics were absolutely right in noting that the entire apparatus of the Hub disciples bears responsibility for this cavalcade of suck.

She did not “sell” anything. Cognate helped them, but Cognate does not own any of NWBO’s IP. Cognate and CRL are not out to develop Dendritic Cell vaccines. Craft from labs also is not really IP that she could own or sell. People adopt what shorts say, to make counter arguments but Cognate / CRL are doing their own thing, and that’s cool. But they don’t own anything from NWBO that they can monetize.

They have experience. They know how to work with different types of cells like Dendritic cells. They have the skilled personnel and equipment and space to do it and a business. But NWBO owns its IP.

>>>they should go to hell for trying to kill a cancer cure therapy.<<<

Cut the faux outrage. Your only interest in this stock is to make money, and your annoyance is because it hasn't happened.

In terms of your phrase 'cancer cure therapy', you may wish to add an asterisked disclaimer next to that emphatic statement.

Unless I'm mistaken, substantial financial penalties could be involved, but unless the Govt. takes on the MM's, this is a civil suit and can't result in jail time. I doubt this will ever go to court where the govt. would see what's presented and could take action. I really believe that the SEC rarely digs into such cases, especially when it comes to OTC stocks, but anything is possible. The SEC has all to often ignored violation of their rules, in 2008 they went so far as to say for a certain period of time naked shorting of bank stocks would be prosecuted. In other words, for some brief period of time they would actually enforce the law. What is the good of having a law that's essentially being ignored and where you announce things are bad enough that you intend to prosecute it, but only for a short period of time.

Some people believe that over a billion shares of naked shorting has occurred here. To put it another way, that would be perhaps a half billion dollars worth of stock being issued that NWBO wasn't paid for if the average short was at $.50. What would NWBO's financial position look like if they had $.5 billion more in cash from sales of stock.

Gary

Beartrap, from my understanding, the Eden method is less
cumbersome and less expensive than the artisan method and has
the capacity to produce at any given time, at least 10 times more
vaccines than the artisan method. I am also under the impression that
right now Advent has the capacity to manufacture yearly only about 1000
DCVax-L vaccines. I hope I am wrong on that but if correct, the artisan
method cannot at this time meet the yearly demand in the UK because
each year there are 3000+ new GBM cases in the UK.

I therefore hope that before MAA approval, while waiting for the Eden validation,
NWBO-Advent will be able to expand the use of the artisan method so as to
increase the number of GBM patients that can be treated in the UK.

It's insane they haven't done anything. I still can't believe she left all those people on the call just hanging in limbo listening to a lot of giggling. Geez.

You obviously ran out of things to say, as if you had any to start with.

Newman, we're in complete agreement if the UK approval comes in sometime in the next month or so and is a surprise. On the other hand, I would suspect that the smarter shorts are trying to slowly unwind their positions without driving the share price up. These people are well served by MM's trying to keep the share price low.

Let's hope it isn't much longer before it becomes clear that Posner's case will go to trial unless the MM's settle prior to that happening. I don't believe the MM's will risk going to trial which would expose them to SEC scrutiny, as well as a substantial risk of a verdict against them that could go into billions, or certainly hundreds of millions. The question may be, does Posner make them an offer to settle quickly, at a lower price, but convince them the longer they take, the higher the price will be. I would certainly hope that her lowest price is in the hundreds of millions.

I believe that no matter when the approval comes we'll have a short squeeze, there are certain people who'll simply have a short position that's so big they can't possibly eliminate it, but they may be trying to reduce it. I know some here who believe that if it takes another 2 months or more before we get the approval the lower $.30's aren't off the table. I don't think that possibility can be denied unless the company has other news that should buoy the stock between now and then. If I were short, I'd be working my way out today, but those who believe we could see low $.30's will probably hold their position in the belief that will happen.

Gary

I consider "legacy" pre reverse split. You been in it that long?

Just proves all along that spoofing exists and jail time for ALL guilty. Jail time baby!

Out of curiosity, does anyone know if people who've had their surgically removed tumors properly preserved also had leukapheresis and that preserved and now are diseased. If so, wouldn't this be ideal for running comparisons between EDEN and Artisan methods used to make the vaccine. I suppose another question would involve making vaccine from properly preserved tumors and leukapheresis from healthy volunteers simply allowing the vaccine to be made for comparison.

Just a thought, trying to figure the best way to compare apples with apples to assure the EDEN meets requirements of the regulators.

Gary

She was sure about securing the MHRA approval; but she did not speculate when because it is in the hands of the MHRA. It could come tomorrow., imo. Nothing can go wrong because rGBM data was amazingly super; nGBM data was not beaten by any biopharma in the past 20+ years; CIs failed trying GBM. There can be no questions on the artisan method which won us the global manufacturing license. Basically I 100% believe the shorts are screwed. They literally don't have time to cover, imo. No mercy for them from me; they should go to hell for trying to kill a cancer cure therapy.

They haven’t even submitted the pricing plan to NICE . I don’t think NICE is or can be in any hurry without that submission .

Yes, shocking the shorts would be wonderful.

Meirluc, I make those predictions (hopeful thoughts, really) with no knowledge of how long it takes to make multiple engineering runs to test compatibility with results from the artisan method. Perhaps there are posters here who have knowledge in this field and can give us their insight on how long it takes.

However, I am convinced that MHRA wants DCVax-L approved as soon as possible, and wants the Eden units approved as soon as possible also because it will cost them less. It's my impression that the artisan method is more costly to operate and will be priced higher by NICE than the automated Eden method.

Please correct me if I'm wrong. As I remember it, NWBO announced that it was making certain material changes in the EDEN to make cleaning and maintenance of it better. I suspect that this was the result of an inspection of the EDEN by regulators who recommended the changes. I don't know this to be the case, but if it were wouldn't it be equally possible to believe the regulators were actually observing the operation of the units and perhaps studying the vaccine being manufactured in them.

I'm not saying this is the case, just looking at possibility. I don't believe the material changes would effect the output of the unit, especially if they're not in the disposable cassette, the only part that ever touches the vaccine. I believe they've ordered production models with the material changes required and hopefully will shortly have some operational at Sawston.

It's clear that LP is playing her cards close to the vest, she was more open about many things anticipated in the next 18 months, but short on specific goals or scheduling, something that is typical of biotech CEO's across the board. This was certainly the best presentation I've seen from her in the few years I've been an investor. I believe that she was being cautious about saying they still expect RFI's rather than saying we're currently at a period that's more than double where this is normally received, so it's very possible there will be no RFI's at all. In the back of my mind I believe that she'd be thrilled with an approval that totally shocked the shorts still working hard to manipulate the stock.

Gary

I am sure the new guys - SIO are feeling great about the deep discount they got on the shares as well.

LP sold the artisan method expertise Cognate to CRL for a billion plus dollar. This method does NOT need any more inspection. LP has chosen the safest way to secure the approval first. We are amazed of her smartness. And she revealed this only at the ASM. The shorts are in big trouble now, LOL. No mercy from us for these bloodsuckers.

I agree with you Beartrap that NWBO has for many years done an
excellent job and I hope that your optimistic timelines for MA approval
(by end of this summer) and EDEN (ready by the end of this year),
are correct.

With respect to the timelines topic, I am convinced that Less
always had the best intentions and it is probably not his fault
but for sometime he has been creating problems with his false
predictions and that has created more problems than solutions.

As noble as you phrase this NICE mission statement, it doesn't change the fact, that there is not the money within the NHS to pay for any of it.

It is about time to slaughter the short pigs, hahaha.

Zadie - as to why there are 1.7 mil pages - go listen again to what LP said about this. It makes sense. Listen and learn.

Newly recent opportunity for DCVax-Direct ???

Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
Fri, Jun 28, 2024, 8:13 AM CDT

https://finance.yahoo.com/news/pharma-stock-roundup-fdas-crl-131300652.html

The FDA issued a complete response letter (“CRL”) to Merck and its partner Daiichi Sankyo’s
biologics license application (BLA) seeking accelerated approval for patritumab deruxtecan
for previously-treated EGFR-mutated non-small cell lung cancer (NSCLC). The CRL was based
on observations made after the inspection of a third-party manufacturing facility. The FDA
has not requested any additional efficacy/safety studies, nor has it identified any issues
related to the safety and efficacy of the candidate.

lol we are the legacy shareholders ..

I wrote off my losses years ago

And own 1000x more shares now than I did then

Your begging for feels on legacy is comical

Every day LC throws fecal matter on the wall to no avail

Another garbage guesstimation from the BASHER LC … if u don’t believe NWBO will be requesting reimbursement on par or greater than OPTUNE or KEYTRUDA.

Then u are truly delusional ..

U have no idea what’s in the submission

This statement by LC is a blatant distortion and or lie ..